Clinical trial NCT01505621: Novel Methodology to Measure Protein Accumulation
Official title: Novel Methodology to Measure Protein Accumulation
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Aging
Keywords: Aging
Protein accumulation
Protein damage
Lead sponsor: Mayo Clinic
Sponsor class: OTHER
First posted: 2012-01-06
Enrollment: 24
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Two groups of otherwise healthy participants will be recruited: young (18-30 years) and old (≥65 years). We anticipate screening up to 30 individuals for each group (up to 60 total for study) in order to enroll 12 individuals for each group (24 total for study). A high ratio of screened to enrolled participants is necessary due to exclusion criteria and concern about finding healthy older participants and relatively inactive younger participants. An equal number of participants will be enrolled in each group. We will attempt to have an equal number of men and women.

Brief summary: Accumulation of damaged proteins is thought to underlie many degenerative conditions, including aging, diabetes, Alzheimer's disease, cataracts, and others. Over time, proteins can be irreversibly damaged by a variety of factors, such as reactive oxygen species, and without timely degradation they can accumulate and aggregate. We believe this can contribute to the development of chronic degenerative disorders.

The purpose of this study is to develop a novel methodology for measuring protein accumulation and test it in two groups of people: young (18-30 years) and old (≥65 years). This methodology will require that people drink a solution of essential amino acids that includes isotopically labeled L\[ring-13C6\]phenylalanine. We will then collect blood and muscle samples, to isolate plasma and skeletal muscle proteins. Participants will return to the study center four more times on a weekly interval.

We hypothesize that older proteins, which persisted in circulation and accumulated over time, will have a higher degree of post-translational oxidative damage than newly synthesized proteins.


Eligibility criteria: Inclusion Criteria:

* Age 18-30 years
* Age greater than 65 years

Exclusion Criteria:

* Active or uncontrolled cardiovascular disease
* Chronic kidney disease with serum creatinine ≥ 1.4 mg/dL for women and ≥ 1.5 mg/dL for men
* Chronic liver disease (elevation in serum transaminases ≥ 3 times the upper limit of normal)
* Any debilitating chronic illness, including malignancy
* Significant malabsorptive state, including prior gastric bypass surgery or inflammatory bowel disease
* Diabetes mellitus (types 1 or 2) or glucose ≥ 110 mg/dL.
* Obesity (BMI ≥ 31 kg/m2)
* Anticoagulant therapy (warfarin or heparin) or bleeding disorder that increases risk of bleeding during a muscle biopsy.
* Anemia (hemoglobin ≤ 11 g/dL)
* Use of medications known to modulate protein synthesis, mitochondrial function, and/or glucose homeostasis (including β-blockers and corticosteroids).
* Participation in another study where the 13CPhe was administered during the past 6 months.
* Moderate or high level of structured exercise (on average, ≥ 30 minutes per day and ≥ 2 days per week)
* Pregnancy
* Daily use of tobacco products (smoking or chewing); or smoking ≥7 cigarettes per week, on average. Abstinence from tobacco for ≥3 months is required before enrollment in the study.

Primary outcomes:
measure: Isotopic enrichment of plasma and skeletal muscle proteins achieved by oral ingestion of [13C6]-phenylalanine
timeFrame: 3 weeks
measure: Degree of post-translational modifications in plasma and muscle proteins
timeFrame: 3 weeks
Secondary outcomes:
measure: Assess differences in protein accumulation as a function of age
timeFrame: 3 weeks
measure: Assess differences in protein modification/damage as a function of age
timeFrame: 3 weeks
Other outcomes:
Locations:
city: Rochester
country: United States
facility: Mayo Clinic
state: Minnesota
Study officials:
References: